Products & Technology
Our cutting-edge screening and diagnostic devices are revolutionizing pre-cancer and cancer detection in the skin and internal organs. *FDA Approval pending.
Vita Imaging’s AURA™ is a patent protected, safe, non-invasive imaging and spectroscopy system designed to aid physicians and healthcare professionals in the early detection of skin cancer by determining malignant from benign skin lesions.
*FDA Approval pending
In Less Than a Second
AURA™ provides valuable information by identifying spectral changes associated with the biochemistry of skin cancer cells and creating a “molecular fingerprint” in less than one second. AURA™ provides immediate, real-time results more rapidly than other skin cancer detection devices in the market.
Our Patent Portfolio
Through its partnership with British Columbia Cancer Agency (BCCA) and the University of British Columbia (UBC), Vita Imaging has licensed a comprehensive patent portfolio to a cutting-edge platform technology with applications for cancer detection in the skin (AURA™) and internal organs
|In Vivo raman endoscopic probe||USA||National||Issued|
|Multimodal detection of tissue abnormalities based on raman and background fluorescence spectroscopy||USA||National||Issued|
|Integrated spectral probe for raman, reflectance and fluorescence spectral measurements||USA||National||Issued|
|Optical standard for calibration of spectral measuring systems||USA
USA issued 2019
China application pending
(to issue in 1-3 years estimated)
|Reflectance confocal microscopy (RCM) Guided Confocal Raman Spectroscopy||USA||National||Issued|
|Apparatus and methods relating to high speed Raman Spectroscopy||USA||National||Issued|
|Endoscopic Raman Spectroscopy Device||USA||National||Issued|
Early Detection Saves Lives
Jointly developed by the British Columbia Cancer Agency (BCCA) and the University of British Columbia (UBC) with extensive testing conducted at Vancouver General Hospital, AURA™ was used in a human clinical study spanning six years on over 800 patients with assessment of over 1,000 lesions. To date, it is the most comprehensive Raman based skin cancer study conducted globally. Results, published in peer-reviewed publications, showed sensitivity of 90% with 82.1% specificity, and sensitivity of 99% with specificity of 44.5% in identifying early stage and malignant skin cancers (actinic keratosis, basal cell carcinoma, squamous cell carcinoma, and melanoma). These performance results are superior to other devices in the market.
Reduced Wait Times–Better Outcomes
AURA™ helps automate the current process of diagnosis by allowing rapid scanning of the 20 to 40 skin lesions on “at risk” individuals and maximizes efficiencies in the workflow by delivering significant clinical impact through improved patient outcomes and reduced wait times. Product development of AURA™ is led by well-respected, award-winning pioneers in the field of cancer imaging. The multi-disciplinary scientific, medical, and technical team is comprised of world-renowned experts in cancer detection.